文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

脑转移瘤切除术后颅内术后腔的分次立体定向放疗——临床结局与预后因素

Fractionated stereotactic radiotherapy of intracranial postoperative cavities after resection of brain metastases - Clinical outcome and prognostic factors.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-04-21

本研究回顾性分析了105例脑转移瘤切除术后接受Cyberknife分次立体定向放疗(35 Gy/7次)的患者,中位随访20.8个月,1年颅内总控制率为61.6%,1年局部控制率为98.6%,中位总生存期为28.7个月(95%CI:16.9-40.5)。无颅外转移是多变量分析中总生存期更优的独立预后因素(p<0.001),而较高的Karnofsky体能状态评分(KPS)在单变量分析中预测更长的总生存期(p=0.041)。作者认为术后分次立体定向放疗是有效且安全的治疗方式,局部控制优异、毒性可接受,但需进一步前瞻性随机试验以建立标准化治疗指南。

要点

  • 105例脑转移瘤切除术后患者接受Cyberknife分次立体定向放疗35 Gy/7次,1年局部控制率98.6%,1年颅内总控制率61.6%。
  • 中位总生存期28.7个月(95%CI:16.9-40.5),无颅外转移为总生存期更优的独立预后因素(p<0.001)。
  • 局部进展发生率为2.0%,放射性对比增强(RICE)发生率为20.4%(中位时间14.3个月),软脑膜疾病发生率为13%。

核心结论

  • 作者认为脑转移瘤切除术后分次立体定向放疗是有效且安全的治疗方式,局部控制优异、毒性可接受。
  • 作者提出需进一步前瞻性随机试验以建立标准化治疗指南。

研究设计与样本

  • 回顾性分析105例脑转移瘤切除术后接受Cyberknife分次立体定向放疗(35 Gy/7次)的患者。
  • 采用Kaplan-Meier法分析总生存期、局部控制和颅内总控制,采用Cox比例风险模型识别预后因素。
  • 中位随访时间为20.8个月。

主要发现

  • 1年颅内总控制率为61.6%,1年局部控制率为98.6%。
  • 中位总生存期为28.7个月(95%CI:16.9-40.5)。
  • 局部进展发生率为2.0%(中位时间未达到),放射性对比增强发生率为20.4%(中位时间14.3个月)。
  • 多变量分析中无颅外转移是总生存期更优的独立预后因素(p<0.001),单变量分析中较高Karnofsky体能状态评分预测更长总生存期(p=0.041)。
  • 软脑膜疾病发生率为13%。

关键数值与推荐

  • 分次立体定向放疗剂量方案为35 Gy分7次,采用Cyberknife实施。
  • 无颅外转移与总生存期更优独立相关(p<0.001,多变量分析)。
  • 较高Karnofsky体能状态评分与更长总生存期相关(p=0.041,单变量分析)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性研究。
  • 作者提出需进一步前瞻性随机试验以建立标准化治疗指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: After surgical resection of brain metastases (BM), radiotherapy (RT) is indicated. Postoperative stereotactic radiosurgery (SRS) reduces the risk of local progression and neurocognitive decline compared to whole brain radiotherapy (WBRT). Aside from the optimal dose and fractionation, little is known about the combination of systemic therapy and postoperative fractionated stereotactic radiotherapy (fSRT), especially regarding tumour control and toxicity. METHODS: In this study, 105 patients receiving postoperative fSRT with 35 Gy in 7 fractions performed with Cyberknife were retrospectively reviewed. Overall survival (OS), local control (LC) and total intracranial brain control (TIBC) were analysed via Kaplan-Meier method. Cox proportional hazards models were used to identify prognostic factors. RESULTS: Median follow-up was 20.8 months. One-year TIBC was 61.6% and one-year LC was 98.6%. Median OS was 28.7 (95%-CI: 16.9-40.5) months. In total, local progression (median time not reached) occurred in 2.0% and in 20.4% radiation-induced contrast enhancements (RICE) of the cavity (after median of 14.3 months) were diagnosed. Absence of extracranial metastases was identified as an independent prognostic factor for superior OS (p = <0.001) in multivariate analyses, while a higher Karnofsky performance score (KPS) was predictive for longer OS in univariate analysis (p = 0.041). Leptomeningeal disease (LMD) developed in 13% of patients. CONCLUSION: FSRT after surgical resection of BM is an effective and safe treatment approach with excellent local control and acceptable toxicity. Further prospective randomized trials are needed to establish standardized therapeutic guidelines.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hahnemann L, Krämer A, Fink C, et al. Fractionated stereotactic radiotherapy of intracranial postoperative cavities after resection of brain metastases - Clinical outcome and prognostic factors. Clin Transl Radiat Oncol. 2024. PMID: 38694237. doi:10.1016/j.ctro.2024.100782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。